Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeted therapy in the treatment of lung cancer in Iceland 2010-2023.

Acta oncologica (Stockholm, Sweden) - 9 Apr 2026

Tryggvadóttir Stefanía Ásta, Stefánsson Guðlaugur V, Birgisson Helgi, Gunnarsson Örvar, Guðbjartsson Tómas, Harðardóttir Hrönn, Hilmarsdóttir Bylgja, Barkardóttir Rósa B, Haraldsdottir Sigurdis

Abstract excerpt

BACKGROUND AND PURPOSE: Lung cancer is the third most common malignancy in Iceland and remains the leading cause of cancer-related mortality. Lung cancer may harbor driver mutations affecting the function of Epidermal growth factor receptor (EGFR), Anaplastic lymphoma kinase (ALK), ROS proto-oncogene 1 (ROS1), B-raf proto-oncogene (BRAF), RET proto-oncogene (RET), MET proto-oncogene (MET), and NTRK, which can...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to ErbB Receptors

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Iceland

Share to Lung Neoplasms

Share to Molecular Targeted Therapy

Share to Protein-Tyrosine Kinases

Share to Proto-Oncogene Mas

Share to Registries

Source

Open in PubMed Open full text

Identifiers

PMID: 41954526
DOI: 10.2340/ao.v65.45118
PMCID: PMC13071797

Genes

EGFR
MET
RET
ALK
BRAF
ROS1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeted therapy in the treatment of lung cancer in Iceland 2010-2023.PMID 41954526Read ↗

Lung Cancer: Targeted Therapy in 2025Semantic proximity Read ↗

Next Generation Sequencing Analysis and its Benefit for Targeted Therapy of Lung Adenocarcinoma.Semantic proximity Read ↗

Somatic gene mutations and their association with treatment outcomes among Indo-Asian Lung Cancer patients.Semantic proximity Read ↗

FIN-EGFRprint: a Finnish real-world study on treatments and outcomes in advanced NSCLC with common EGFR mutations.Semantic proximity Read ↗

The Utility of Tissue-Agnostic Drugs in Lung Cancer Treatment.Semantic proximity Read ↗

Actionable NSCLC Mutation Identification by Comprehensive Genomic Profiling for Clinical Trial Enrollment: The European Program for the Routine Testing of Patients With Advanced Lung Cancer (EPROPA).Semantic proximity Read ↗

Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update.Semantic proximity Read ↗

Exploring AI tools and multi-omics for precision medicine in lung cancer therapy.Semantic proximity Read ↗

Real-World Survival Outcomes in Non-Small Cell Lung Cancer: The Impact of Genomic Testing and Targeted Therapies in a Latin American Middle-Income Country.Semantic proximity Read ↗

Genomic Landscape of NSCLC in the Republic of IrelandSemantic proximity Read ↗

Clinical testing for molecular targets for personalized treatment in lung cancer.Semantic proximity Read ↗

[The application of target-based tissue-agnostic therapy in the treatment of lung cancer].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.